stockportfolio.pro
Cencora, Inc. (COR)
Healthcare · Medical Distribution · NYSE
Cencora, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $146.85B | $153.14B | $167.94B | $179.59B | $189.89B | $213.99B | $238.59B | $262.17B | $293.96B | $321.33B |
| Gross profit | $4.27B | $4.55B | $4.61B | $5.14B | $5.19B | $6.94B | $8.30B | $8.96B | $9.91B | $11.48B |
| Net income | $1.43B | $364.48M | $1.66B | $855.37M | $-3.41B | $1.54B | $1.70B | $1.75B | $1.51B | $1.55B |
| Net margin | 1.0% | 0.2% | 1.0% | 0.5% | -1.8% | 0.7% | 0.7% | 0.7% | 0.5% | 0.5% |
Source: Cencora, Inc. SEC filings (10-K). 19 years of history available in the interactive view.
What growth is priced into COR stock?
At today's market cap of $54.39B, Cencora, Inc. is priced for free-cash-flow growth of about 5.5% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $3.21B from the FY ending 2025-09-30). For comparison, free cash flow actually grew 11.8%/yr over the last five fiscal years and revenue 11.1%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 19 years of Cencora, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track COR in your portfolio →
Cencora, Inc. financial history by metric
About Cencora, Inc.
Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; distributes plasma and other blood products, vaccines, and other specialty pharmaceutical products; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; sales force services to manufacturers; and offers other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment provides international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals; and offers specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was founded in 1871 and is headquartered in Conshohocken, Pennsylvania.
Cencora, Inc. — frequently asked questions
What is Cencora, Inc.'s revenue?
Cencora, Inc. (COR) reported revenue of $321.33B for fiscal year 2025, up 9.3% from the prior year, according to its SEC filings.
Is Cencora, Inc. profitable?
Yes. COR earned net income of $1.55B in fiscal 2025, a net margin of 0.5%.
What is COR's P/E ratio?
Cencora, Inc. trades at a price-to-earnings ratio of about 21.4 based on the latest data in our nightly-refreshed cache.
How fast is Cencora, Inc. growing?
COR's revenue grew at roughly 11.1% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Cencora, Inc. have?
As of fiscal year 2025, COR carried roughly $7.78B in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Cencora, Inc.'s gross margin?
COR's gross margin was 3.6% in fiscal 2025 — gross profit of $11.48B on revenue of $321.33B.
What is Cencora, Inc.'s market cap?
Cencora, Inc. (COR) has a market capitalization of about $54.39B, based on the latest data in our nightly-refreshed cache.
When does Cencora, Inc.'s fiscal year end?
COR's fiscal year ends in September. Its most recent annual filing covers the fiscal year ending 2025-09-30.
What growth is priced into COR stock?
At today's market cap of $54.39B, Cencora, Inc. is priced for free-cash-flow growth of about 5.5% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $3.21B from the FY ending 2025-09-30). For comparison, free cash flow actually grew 11.8%/yr over the last five fiscal years and revenue 11.1%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from Cencora, Inc.'s official SEC filings (10-K and 10-Q), covering 19 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.